Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Credit agrmnt [a]
Gossamer Bio, Inc. (GOSS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update - Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 -"
07/20/2023 8-K Quarterly results
07/20/2023 8-K Quarterly results
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GOSSAMER BIO, INC."
05/09/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update - Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study -"
04/03/2023 8-K Other Events  Interactive Data
03/17/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update - FDA Feedback on Seralutinib Phase 3 Clinical Trial Received&#59; Expected to Commence in the Second Half of 2023 -"
12/06/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/25/2022 8-K Results of Operations and Financial Condition, Other Events
03/03/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Topline Results from Ongoing Phase 2 TORREY Study of Seralutinib in Patients with PAH Now Expected in Second Half of 2022, Due to COVID-19-Related Delays -"
10/12/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208"
09/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role"
08/09/2021 8-K Quarterly results
06/14/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/20/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/17/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/10/2020 8-K Quarterly results
Docs: "Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update - GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis -"
10/13/2020 8-K Quarterly results
08/11/2020 8-K Quarterly results
07/02/2020 8-K Quarterly results
06/18/2020 8-K Quarterly results
05/21/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Underwriting Agreement, related to the Common Stock",
"Underwriting Agreement, datedMay 18, 2020, related to the Notes",
"Indenture",
"First Supplemental Indenture",
"Opinion of Latham & Watkins LLP, related to the Common Stock",
"Opinion of Latham & Watkins LLP, related to the Notes",
"Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027",
"Gossamer Bio Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027"
05/12/2020 8-K Quarterly results
Docs: "Gossamer Bio Statement of Operations Condensed Consolidated Statement of Operations Three months ended March 31,"
03/24/2020 8-K Quarterly results
01/13/2020 8-K Regulation FD Disclosure
11/12/2019 8-K Quarterly results
Docs: "Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of September 30, 2019, were $446.5 million. The Company expects current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the fourth quarter of 2021. • Research and Development Expenses: For the quarter ended September 30, 2019, R&D expenses were $40.1 million, including $2.7 million of stock-based compensation, compared to R&D expenses of $18.9 million for the quarter ended September 30, 2018. The increase was primarily due to an increase in expenses for GB001, GB002, GB004 and GB1275. • In-Process Research and Development Expenses: For the quarter ended September 30, 2019,..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy